You may have heard that CBD is a great way to boost your levels of anandamide. I evaluate the evidence and see that the case for this is weak: https://t.co/T2w9f0YQw2
Tetrahydrocannabiphorol (THCP) is the latest cannabinoid. What do we actually know about it and what could happen once it is commercialized? https://t.co/HOhckTfuZi
The noradrenergic system is not as famous as the serotonergic or dopaminergic systems, but it is still important for several effects of cannabinoids: https://t.co/oKozekiAaT
Your genetics determine part of your risk for developing PTSD. Genetic variants in the cannabinoid CB1 receptor and FAAH enzyme contribute to this: https://t.co/Ai903RXC1c
Serotonin is important for regulating pain, mood, cognition, and more. Here is why the serotonergic system is important for certain effects of THC and CBD: https://t.co/R8sl83fPz4
The endocannabinoid system may be involved in the pathophysiology of depression, but it may also offer new opportunities for treatment:
https://t.co/XLdrLbM3DG
@cannaworldsite@CannifyUS@TheWeedBlog I acknowledge not minor by abundance in the plant (I state this in the first paragraph of the article). But minor based on consumption and how much we know about it.
THCA is a minor cannabinoid that can potently activate a nuclear receptor called PPARγ. Although it could be neuroprotective, we have no data from clinical trials: https://t.co/m7Mb4UDotr
CBN is claimed to have sedative and sleep-promoting effects. The problem is that very little of the extensive research on CBN actually support this: https://t.co/bLynceyuAH
CBDA is much more potent at the 5-HT1A receptor than CBD. This could mean improved therapy for nausea/vomiting and anxiety, but clinical trials are lacking: https://t.co/LRv6V1X9Dh
CBDV is a minor cannabinoid with activity in animal models of epilepsy, autism spectrum disorders, and neuropathic pain. Several clinical trials have been initiated in these conditions: https://t.co/nyfV7OcSQI
THCV is a minor cannabinoid which can block activation of the CB1 receptor. Although it had potential in type 2 diabetes, it failed a Phase 2 trial: https://t.co/yxrKTlmDF3
The therapeutic potential of minor cannabinoids is often exaggerated. Here are 5 things you need to know to critically evaluate the latest research: https://t.co/565QqU6gD0
The cannabinoid CB2 receptor has important regulatory functions in the brain. Your risk of several psychiatric diseases may be heightened if you have certain genetic variants: https://t.co/PCfdnnIBz0
The cannabinoid CB2 receptor is critical for limiting inflammation. Your risk of many immune diseases may be heightened if you have this genetic variant: https://t.co/D0PjBML4WB
Cannabis has been linked to aggression despite having the opposite effect in most people. A polymorphism in the serotonin 5-HT2B receptor may be one explanation: https://t.co/umRDlLpVPv
People with low activity of the GABA-A receptor are more susceptible to psychotomimetic effects of THC. Here’s how some cannabis terpenes may help: https://t.co/UPrwk3hF5y